Your browser doesn't support javascript.
loading
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.
Chehrazi-Raffle, Alexander; Leong, Sally; Ali, Sana; Kim, Tane; Melamed, Sam; Li, Xiaochen; Zengin, Zeynep; Meza, Luis; Chawla, Neal; Govindarajan, Ameish; Castro, Daniela; Mercier, Benjamin; Ebrahimi, Hedyeh; Dizman, Nazli; Tripathi, Nishita; Sayegh, Nicolas; Rock, Adam; Yeh, James; Pal, Sumanta K; Onyshchenko, Mykola.
Afiliação
  • Chehrazi-Raffle A; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Leong S; Division of Hematology and Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
  • Ali S; Division of Hematology and Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
  • Kim T; Division of Cancer Biology and Immunotherapeutics, The Lundquist Institute, Torrance, CA, USA.
  • Melamed S; Division of Cancer Biology and Immunotherapeutics, The Lundquist Institute, Torrance, CA, USA.
  • Li X; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Zengin Z; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Meza L; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Chawla N; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Govindarajan A; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Castro D; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Mercier B; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Ebrahimi H; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Dizman N; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Tripathi N; Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Sayegh N; Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Rock A; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Yeh J; Division of Hematology and Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
  • Pal SK; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Onyshchenko M; Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Oncologist ; 28(12): 1079-1084, 2023 Dec 11.
Article em En | MEDLINE | ID: mdl-37432304
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Antineoplásicos Imunológicos / Inibidores de Checkpoint Imunológico / Neoplasias Renais Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Antineoplásicos Imunológicos / Inibidores de Checkpoint Imunológico / Neoplasias Renais Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos